$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[국내논문] Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition 원문보기

Journal of Korean medical science : JKMS, v.29 no.4, 2014년, pp.468 - 484  

Won, Eunsoo (Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea.) ,  Park, Seon-Cheol (Department of Psychiatry, Yong-In Mental Hospital, Yongin, Korea.) ,  Han, Kyu-Man (Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea.) ,  Sung, Seung-Hwan (Department of Psychiatry, College of Medicine, Soonchunhyang University, Asan, Korea.) ,  Lee, Hwa-Young (Department of Psychiatry, College of Medicine, Soonchunhyang University, Asan, Korea.) ,  Paik, Jong-Woo (Department of Psychiatry, School of Medicine, KyungHee University, Seoul, Korea.) ,  Jeon, Hong Jin (Department of Psychiatry, School of Medicine, Sungkyunkwan University, Seoul, Korea.) ,  Lee, Moon-Soo (Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea.) ,  Shim, Se-Hoon (Department of Psychiatry, College of Medicine, Soonchunhyang University, Asan, Korea.) ,  Ko, Young-Hoon (Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea.) ,  Lee, Kang-Joon (Department of Psychiatry, College of Medicine, Inje Universtiy, Busan, Korea.) ,  Han, Changsu (Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea.) ,  Ham, Byung-Joo (Department of) ,  Choi, Joonho ,  Hwang, Tae-Yeon ,  Oh, Kang-Seob ,  Hahn, Sang-Woo ,  Park, Yong-Chon ,  Lee, Min-Soo

Abstract AI-Helper 아이콘AI-Helper

This paper aims to introduce, summarize, and emphasize the importance of the 'Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition'. The guideline broadly covers most aspects of the pharmacological treatment of patients in Korea diagnosed with moderate to seve...

Keyword

참고문헌 (87)

  1. 1 Lopez AD Mathers CD Ezzati M Jamison DT Murray CJL Global burden of disease and risk factors Washington, D.C. World Bank 2006 

  2. 2 Lee MS Cha JH Chung SK Kim KS Kasper S the Executive Committee for the Korean Medication Algorithm Project for Major Depressive Disorder The development of the Korean medication algorithm for major depressive disorder Psychiatry Investig 2005 2 60 69 

  3. 3 Clinical Research Center for Depression Evidence-based Korean pharmacological treatment guideline for depression Seoul ML Communication 2008 

  4. 4 Park SC Oh HS Oh DH Jung SA Na KS Lee HY Kang RH Choi YK Lee MS Park YC Evidence-based, non-pharmacological treatment guideline for depression in Korea J Korean Med Sci 2014 29 12 22 24431900 

  5. 5 Clinical Research Center for Depression Evidence-based Korean pharmacological treatment guideline for depression, revised edition Seoul ML Communication 2012 

  6. 6 Park SC Sung SH Han KM Won ES Lee HY Paik JW Jeon HJ Lee MS Shim SH Ko YH Evidence-based Korean pharmacological treatment guideline for depression, revised edition (I): initial choice of antidepressant treatment J Korean Neuropsychiatr Assoc 2013 52 253 262 

  7. 7 Sung SH Park SC Han KM Won ES Lee HY Koo JW Paik JW Lee KM Jeon HJ Lee MS Evidence-based Korean pharmacological treatment guideline for depression, revised edition (II): antidepressant efficacy compared with placebo, difference in efficacy of antidepressants, and appropriate time of efficacy judgment in antidepressant therapy J Korean Neuropsychiatr Assoc 2013 52 372 385 

  8. 8 Han KM Park SC Won ES Sung SH Lee H Koo JW Lee K Lee HY Paik JW Jeon HJ Evidence-based Korean pharmacological treatment guideline for depression, revised edition (III): dose increment, switching, combination, and augmentation strategy in antidepressant therapy J Korean Neuropsychiatr Assoc 2013 52 386 401 

  9. 9 Huang X Lin J Demner-Fushman D Evaluation of PICO as a knowledge representation for clinical questions AMIA Annu Symp Proc 2006 359 363 17238363 

  10. 10 Kim SY KN Shin SS Kim DW Ji SM Lee SJ ADAPTE: manual for guildeline adaptation version 1.0 Seoul National Clinical Research Coordination Center 2009 

  11. 11 Guyatt GH Oxman AD Kunz R Falck-Ytter Y Vist GE Liberati A Schünemann HJ; GRADE Working Group Going from evidence to recommendations BMJ 2008 336 1049 1051 18467413 

  12. 12 National Institute for Health and Clinical Excellence (NICE) Depression: the treatment and management of depression in adults (updated edition) Leicester British Psychological Society 2010 

  13. 13 Anderson IM Ferrier IN Baldwin RC Cowen PJ Howard L Lewis G Matthews K McAllister-Williams RH Peveler RC Scott J Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines J Psychopharmacol 2008 22 343 396 18413657 

  14. 14 The New Zealand guidelines group Identification of common mental disorders and management of depression in primary care New Zealand Ministry of Health 2008 

  15. 15 Malhi GS Adams D Porter R Wignall A Lampe L O'Connor N Paton M Newton LA Walter G Taylor A Clinical practice recommendations for depression Acta Psychiatr Scand Suppl 2009 439 8 26 19356154 

  16. 16 Practice guideline for the treatment of patients with major depressive disorder (revision): American Psychiatric Association Am J Psychiatry 2000 157 1 45 

  17. 17 Lam RW Kennedy SH Grigoriadis S McIntyre RS Milev R Ramasubbu R Parikh SV Patten SB Ravindran AV Canadian Network for Mood and Anxiety Treatments (CANMAT) Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: III. pharmacotherapy J Affect Disord 2009 117 S26 S43 19674794 

  18. 18 Montgomery SA A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression Int Clin Psychopharmacol 2001 16 169 178 11354239 

  19. 19 Puech A Montgomery SA Prost JF Solles A Briley M Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability Int Clin Psychopharmacol 1997 12 99 108 9219045 

  20. 20 Anderson IM Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability J Affect Disord 2000 58 19 36 10760555 

  21. 21 Bauer M Bschor T Pfennig A Whybrow PC Angst J Versiani M Möller HJ; WFSBP Task Force on Unipolar Depressive Disorders World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders in primary care World J Biol Psychiatry 2007 8 67 104 17455102 

  22. 22 Simon GE VonKorff M Heiligenstein JH Revicki DA Grothaus L Katon W Wagner EH Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants JAMA 1996 275 1897 1902 8648870 

  23. 23 Vaswani M Linda FK Ramesh S Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review Prog Neuropsychopharmacol Biol Psychiatry 2003 27 85 102 12551730 

  24. 24 Professional Development & Quality Assurance prepared by a group of family physicians Guideline on Management of Depression in Primary Care Hong Kong 2005 

  25. 25 Qaseem A Snow V Denberg TD Forciea MA Owens DK Clinical Efficacy Assessment Subcommittee of American College of Physicians Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians Ann Intern Med 2008 149 725 733 19017591 

  26. 26 Texas Department of Mental Health and Mental Retardation (TDMHMR) in collaboration with Texas universities Texas medication algorithm project procedural manual - major depressive disorder algorithms Texas Department of State Health Services 2008 

  27. 27 Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology Korean medication algorithm project for depressive disorder Korean Neuropsychiatr Assoc 2008 

  28. 28 Moscovitch A Blashko CA Eagles JM Darcourt G Thompson C Kasper S Lane RM International Collaborative Group on Sertraline in the Treatment of Outpatients with Seasonal Affective Disorders A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder Psychopharmacology (Berl) 2004 171 390 397 14504682 

  29. 29 Lam RW Gorman CP Michalon M Steiner M Levitt AJ Corral MR Watson GD Morehouse RL Tam W Joffe RT Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder Am J Psychiatry 1995 152 1765 1770 8526243 

  30. 30 Ruhrmann S Kasper S Hawellek B Martinez B Höflich G Nickelsen T Möller HJ Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder Psychol Med 1998 28 923 933 9723147 

  31. 31 Bodkin JA Amsterdam JD Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients Am J Psychiatry 2002 159 1869 1875 12411221 

  32. 32 Amsterdam JD A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder J Clin Psychiatry 2003 64 208 214 12633131 

  33. 33 Feiger AD Rickels K Rynn MA Zimbroff DL Robinson DS Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial J Clin Psychiatry 2006 67 1354 1361 17017821 

  34. 34 Khan A Khan SR Leventhal RM Brown WA Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database Int J Neuropsychopharmacol 2001 4 113 118 11466159 

  35. 35 Bech P Cialdella P Haugh MC Birkett MA Hours A Boissel JP Tollefson GD Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression Br J Psychiatry 2000 176 421 428 10912216 

  36. 36 Bech P Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression Int J Neuropsychopharmacol 2001 4 337 345 11806859 

  37. 37 Modell JG Rosenthal NE Harriett AE Krishen A Asgharian A Foster VJ Metz A Rockett CB Wightman DS Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL Biol Psychiatry 2005 58 658 667 16271314 

  38. 38 Fava M Rush AJ Thase ME Clayton A Stahl SM Pradko JF Johnston JA 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL Prim Care Companion J Clin Psychiatry 2005 7 106 113 16027765 

  39. 39 Pitts WM Fann WE Halaris AE Dressler DM Sajadi C Snyder S Ilaria RL Bupropion in depression: a tri-center placebo-controlled study J Clin Psychiatry 1983 44 95 100 6406473 

  40. 40 Barbui C Hotopf M Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials Br J Psychiatry 2001 178 129 144 11157426 

  41. 41 Guaiana G Barbui C Hotopf M Amitriptyline versus other types of pharmacotherapy for depression Cochrane Database Syst Rev 2003 2 CD004186 12804503 

  42. 42 Angst J Amrein R Stabl M Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies J Clin Psychopharmacol 1995 15 16S 23S 7593725 

  43. 43 Cipriani A Brambilla P Furukawa T Geddes J Gregis M Hotopf M Malvini L Barbui C Fluoxetine versus other types of pharmacotherapy for depression Cochrane Database Syst Rev 2005 4 CD004185 16235353 

  44. 44 MacGillivray S Arroll B Hatcher S Ogston S Reid I Sullivan F Williams B Crombie I Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis BMJ 2003 326 1014 12742924 

  45. 45 Arroll B Elley CR Fishman T Goodyear-Smith FA Kenealy T Blashki G Kerse N Macgillivray S Antidepressants versus placebo for depression in primary care Cochrane Database Syst Rev 2009 3 CD007954 19588448 

  46. 46 Panzer MJ Are SSRIs really more effective for anxious depression? Ann Clin Psychiatry 2005 17 23 29 15941028 

  47. 47 Geddes JR Freemantle N Mason J Eccles MP Boynton J SSRIs versus other antidepressants for depressive disorder Cochrane Database Syst Rev 2000 2 CD001851 10796826 

  48. 48 Barbui C Hotopf M Freemantle N Boynton J Churchill R Eccles MP Geddes JR Hardy R Lewis G Mason JM Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence Cochrane Database Syst Rev 2000 4 CD002791 11034764 

  49. 49 Kennedy SH Andersen HF Lam RW Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis J Psychiatry Neurosci 2006 31 122 131 16575428 

  50. 50 Gartlehner G Gaynes BN Hansen RA Thieda P DeVeaugh-Geiss A Krebs EE Moore CG Morgan L Lohr KN Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians Ann Intern Med 2008 149 734 750 19017592 

  51. 51 Bauer M Tharmanathan P Volz HP Moeller HJ Freemantle N The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis Eur Arch Psychiatry Clin Neurosci 2009 259 172 185 19165525 

  52. 52 Perahia DG Pritchett YL Kajdasz DK Bauer M Jain R Russell JM Walker DJ Spencer KA Froud DM Raskin J A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder J Psychiatr Res 2008 42 22 34 17445831 

  53. 53 Thase ME Pritchett YL Ossanna MJ Swindle RW Xu J Detke MJ Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder J Clin Psychopharmacol 2007 27 672 676 18004135 

  54. 54 Smith D Dempster C Glanville J Freemantle N Anderson I Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis Br J Psychiatry 2002 180 396 404 11983635 

  55. 55 Schatzberg AF Kremer C Rodrigues HE Murphy GM Jr Mirtazapine vs. Paroxetine Study Group Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients Am J Geriatr Psychiatry 2002 10 541 550 12213688 

  56. 56 Benkert O Szegedi A Kohnen R Mirtazapine compared with paroxetine in major depression J Clin Psychiatry 2000 61 656 663 11030486 

  57. 57 Papakostas GI Fava M Thase ME Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches Biol Psychiatry 2008 63 699 704 17919460 

  58. 58 Papakostas GI Stahl SM Krishen A Seifert CA Tucker VL Goodale EP Fava M Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies J Clin Psychiatry 2008 69 1287 1292 18605812 

  59. 59 Montgomery SA Baldwin DS Blier P Fineberg NA Kasper S Lader M Lam RW Lépine JP Möller HJ Nutt DJ Which antidepressants have demonstrated superior efficacy? a review of the evidence Int Clin Psychopharmacol 2007 22 323 329 17917550 

  60. 60 Bollini P Pampallona S Tibaldi G Kupelnick B Munizza C Effectiveness of antidepressants: meta-analysis of dose-effect relationships in randomised clinical trials Br J Psychiatry 1999 174 297 303 10533547 

  61. 61 Rudolph RL Feiger AD A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression J Affect Disord 1999 56 171 181 10701474 

  62. 62 Adli M Baethge C Heinz A Langlitz N Bauer M Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? a systematic review Eur Arch Psychiatry Clin Neurosci 2005 255 387 400 15868067 

  63. 63 Amsterdam JD Berwish NJ High dose tranylcypromine therapy for refractory depression Pharmacopsychiatry 1989 22 21 25 2710808 

  64. 64 Gagiano CA Müller FG Berk M Joubert PM Brown RG Schall R Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three times daily dosage schedules J Clin Psychopharmacol 1995 15 4S 9S 7593729 

  65. 65 Burke WJ Gergel I Bose A Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients J Clin Psychiatry 2002 63 331 336 12000207 

  66. 66 Bech P Tanghøj P Andersen HF Overø K Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression Psychopharmacology (Berl) 2002 163 20 25 12185396 

  67. 67 Schweizer E Rickels K Amsterdam JD Fox I Puzzuoli G Weise C What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry 1990 51 8 11 2403998 

  68. 68 Rudolph RL Fabre LF Feighner JP Rickels K Entsuah R Derivan AT A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression J Clin Psychiatry 1998 59 116 122 9541154 

  69. 69 Schweizer E Weise C Clary C Fox I Rickels K Placebo-controlled trial of venlafaxine for the treatment of major depression J Clin Psychopharmacol 1991 11 233 236 1918421 

  70. 70 Rush AJ Trivedi MH Wisniewski SR Stewart JW Nierenberg AA Thase ME Ritz L Biggs MM Warden D Luther JF Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression N Engl J Med 2006 354 1231 1242 16554525 

  71. 71 Ruhé HG Huyser J Swinkels JA Schene AH Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review J Clin Psychiatry 2006 67 1836 1855 17194261 

  72. 72 Nelson JC Mazure CM Jatlow PI Bowers MB Jr Price LH Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study Biol Psychiatry 2004 55 296 300 14744472 

  73. 73 Lader M Combined use of tricyclic antidepressants and monoamine oxidase inhibitors J Clin Psychiatry 1983 44 20 24 6355073 

  74. 74 Carpenter LL Yasmin S Price LH A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine Biol Psychiatry 2002 51 183 188 11822997 

  75. 75 McGrath PJ Stewart JW Fava M Trivedi MH Wisniewski SR Nierenberg AA Thase ME Davis L Biggs MM Shores-Wilson K Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR * D report Am J Psychiatry 2006 163 1531 1541 16946177 

  76. 76 Lam RW Hossie H Solomons K Yatham LN Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression J Clin Psychiatry 2004 65 337 340 15096072 

  77. 77 Dodd S Horgan D Malhi GS Berk M To combine or not to combine? a literature review of antidepressant combination therapy J Affect Disord 2005 89 1 11 16169088 

  78. 78 Maes M Vandoolaeghe E Desnyder R Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression J Affect Disord 1996 41 201 210 8988452 

  79. 79 Nelson JC Overcoming treatment resistance in depression J Clin Psychiatry 1998 59 13 19 9796861 

  80. 80 Nemeroff CB Augmentation strategies in patients with refractory depression Depress Anxiety 1996 4 169 181 9166649 

  81. 81 Shelton RC Treatment options for refractory depression J Clin Psychiatry 1999 60 57 61 10086483 

  82. 82 Barbosa L Berk M Vorster M A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes J Clin Psychiatry 2003 64 403 407 12716240 

  83. 83 Schindler F Anghelescu IG Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study Int Clin Psychopharmacol 2007 22 179 182 17414745 

  84. 84 Fava M Thase ME DeBattista C Doghramji K Arora S Hughes RJ Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness Ann Clin Psychiatry 2007 19 153 159 17729016 

  85. 85 DeBattista C Doghramji K Menza MA Rosenthal MH Fieve RR Modafinil in Depression Study Group Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study J Clin Psychiatry 2003 64 1057 1064 14628981 

  86. 86 Gunnell D Saperia J Ashby D Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review BMJ 2005 330 385 15718537 

  87. 87 Taylor MJ Rudkin L Hawton K Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials J Affect Disord 2005 88 241 254 16162361 

활용도 분석정보

상세보기
다운로드
내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

관련 콘텐츠

오픈액세스(OA) 유형

GOLD

오픈액세스 학술지에 출판된 논문

이 논문과 함께 이용한 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로